Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Guideline on the management of acute chest syndrome in sickle cell disease
source: British Journal of Haematology
year: 2015
authors: Jo Howard, Nicholas Hart, Marilyn Roberts-Harewood, Michelle Cummins, Moji Awogbade, Bernard Davis
summary/abstract:Sickle cell disease (SCD) affects 12 000–15 000 individuals in the UK. Whilst homozygous SCD (sickle cell anaemia — HbSS) is the most common and severe genotype, and is where most of the evidence exists, this guidance should be used for all genotypes of SCD.
Acute chest syndrome (ACS) is defined as an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on chest X-ray (Charache et al, 1979; Ballas et al, 2010). This definition encompasses cases both where an infective organism is isolated and where no infective cause is identified. It is unique to SCD but in some cases ACS may appear to be similar to bacterial pneumonia in a patient without SCD. ACS may have a severe clinical course and can progress rapidly from mild hypoxia to respiratory failure and death. The presence of hypoxia is not included in the definition, but in clinical practice, hypoxia is a useful predictor of severity and outcome (Vichinsky et al, 1997, 2000).
Historically, ACS is one of the most common causes of death in patients with SCD (Platt et al, 1994; Lucas et al, 2008), although mortality is improving with improved medical management (Fitzhugh et al, 2010). ACS can also be associated with significant morbidity, including long-term parenchymal lung damage, pulmonary vascular abnormality and neurological sequelae. Patients may present to hospital acutely unwell with ACS or ACS may develop during a hospital admission following a painful crisis or post-operatively.
organization: Guy's and St Thomas' NHS Foundation Trust, London; St Thomas' Hospital, London; North Middlesex Hospital, London; Bristol Royal Hospital for Children, London; King's College Hospital, London; Whittington Hospital, London.DOI: 10.1111/bjh.13348
read more full text
Related Content
-
Sickle Cell Disease: Pain ManagementPain is a long-lasting problem for peopl...
-
Metabolic Syndrome Risk Among Adults Living with Sickle Cell DiseaseBackground: The life span of individuals...
-
New Guidelines for Managing Sickle Cell Disease Presented at ACP Internal Medicine MeetingNew guidelines for therapeutic strategie...
-
Mental Health Resources for Black, Indigenous and People of Color (BIPOC)In addition to COVID-19, recent events h...
-
Hydroxyurea linked to ‘significant, rapid’ reduction of sperm countSix months of hydroxyurea therapy detrim...
-
A Man With Sickle Cell Disease and HeadacheApproximately 17% of patients with sickl...
-
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Cr...SANGUINATE™, the only investigational ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.